Intuitive Surgical, Inc.
Intuitive Surgical, Inc. develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. It offers the da Vinci Surgical System that enables surgical procedures using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic endoluminal procedures enabling minimally invasive biopsies in the lung. The company also provides a suite of stapling, energy, and core instrumentation for its multi-port da Vinci surgical systems; progressive learning pathways to support the use of its technology; infrastructure of customer service and support specialists, a complement of services to its customers, including installation, repair, maintenance, 24/7 technical support, and proactive system health monitoring; and integrated digital capabilities providing connected offerings, streamlining performance for hospitals with program-enhancing insights. It sells its products through direct sales organizations, such as capital and clinical sales teams. Intuitive Surgical, Inc. was incorporated in 1995 and is headquartered in Sunnyvale, California.
What does it do?
Intuitive Surgical makes robotic surgery systems — think of it as giving surgeons a highly precise robotic set of hands to operate with. Their flagship product, the da Vinci Surgical System, lets doctors perform complex operations through tiny incisions instead of large cuts, which means patients heal faster and with less pain. Surgeons sit at a console a few feet away and control robotic arms that hold tiny instruments inside the patient's body. Over 10,000 da Vinci systems are now installed in hospitals around the world, and they're used for everything from prostate removal to heart valve repair.
Robotic surgery is one of the fastest-growing areas in healthcare, and Intuitive Surgical is the dominant player with roughly 80% market share — it essentially invented the commercial market. Hospitals that buy a da Vinci system tend to keep using it for years, locking in a steady stream of follow-on revenue, which is the kind of business model investors love. With an aging global population needing more surgeries, and healthcare systems in Asia and Europe still early in their robotic adoption, the runway for growth is genuinely long.
How does it make money?
Intuitive makes money in three ways. First, it sells the da Vinci systems themselves, which cost between $1 million and $2.5 million each. Second — and this is the recurring revenue engine — hospitals must buy proprietary instruments and accessories for every single procedure, which typically adds $700 to $3,500 per surgery. Third, it charges for service contracts to maintain the machines. Of the $10.1 billion in revenue reported for the latest year, the instruments, accessories, and services segments make up the majority, meaning revenue keeps flowing long after the initial robot sale.
Why do investors care?
The growth story here is about volume — the more surgeries performed on da Vinci systems, the more consumables Intuitive sells, regardless of whether hospitals are buying new robots. Revenue grew from $8.4 billion to $10.1 billion in a single year, a jump of roughly 20%, which is exceptional for a company this size. Expansion into new procedure types, like lung biopsies via their Ion system, opens entirely new markets beyond traditional surgery. For the thesis to work, procedure volumes need to keep growing, and international markets — especially in China and Europe — need to continue adopting robotic surgery.
Deep Dive
MemberA full investor briefing on Intuitive Surgical, Inc. — history, leadership, risks, and outlook.